AER-01 is currently being evaluated in a Phase 2a clinical trial underway in Australia, New Zealand, and the United Kingdom. The study is assessing the safety and efficacy of once-daily dosing over 28 days in patients with moderate-to-severe COPD, with a focus on improvement in lung function. Preliminary results are anticipated in Q2 2026.